Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia

Expert Review of Neurotherapeutics

Volumn 11, Issue 10, 2011, Pages 1389-1397

  Kohsaka, Masako ^a   Kanemura, Takashi ^b   Taniguchi, Mitsutaka ^c   Kuwahara, Hiroo ^d   Mikami, Akira ^e   Kamikawa, Kunihisa ^f   Uno, Hideki ^f   Ogawa, Atsushi ^f   Murasaki, Mitsukuni ^g   Sugita, Yoshiro ^e  

^a Ishikane Hospital   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^g Institute of CNS Pharmacology   (Japan)

Author keywords

insomnia; melatonin; polysomnographic evaluation; ramelteon; sleep latency; sleep time

Indexed keywords

PLACEBO; RAMELTEON;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ETHNIC DIFFERENCE; FEMALE; HEADACHE; HUMAN; INSOMNIA; JAPANESE; LATENT PERIOD; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL PATIENT; POLYSOMNOGRAPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SLEEP PARAMETERS; SOMNOLENCE; UNITED STATES;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; QUESTIONNAIRES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053554773     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.128     Document Type: Article

References (24)

1. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr. Serv. 56, 332-343 (2005) (Pubitemid 40333567)
2. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J. Clin. Sleep Med. 3(5 Suppl.), S7-S10 (2007)
3. Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep 23, 41-47 (2000) (Pubitemid 30080720)
4. Buscemi N, Vandermeer B, Friesen C et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J. Gen. Intern. Med. 22, 1335-1350 (2007) (Pubitemid 47247294)
5. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can. Med. Assoc. J. 162, 225-233 (2000) (Pubitemid 30073249)
6. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am. Fam. Physician 76, 517-526 (2007)
7. Doghramji K. Melatonin and its receptors: a new class of sleep-promoting agents. J. Clin. Sleep Med. 3(5 Suppl.), S17-S23 (2007)
8. Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48, 301-310 (2005) (Pubitemid 40208266)
9. Reynoldson JN, Elliott E Sr, Nelson LA. Ramelteon: a novel approach in the treatment of insomnia. Ann. Pharmacother. 42, 1262-1271 (2008)
10. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J. Clin. Pharmacol. 46(2), 140-148 (2006) (Pubitemid 43146444)
11. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 7, 17-24 (2006) (Pubitemid 43033540)
12. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 32, 351-360 (2009)
13. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 7, 312-318 (2006) (Pubitemid 43792892)
14. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteons efficacy and safety in older adults with chronic insomnia. Curr. Med. Res. Opin. 23, 1005-1014 (2007) (Pubitemid 46799582)
15. Hirai K, Kita M, Ohta H et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J. Biol. Rhythms 20, 27-37 (2005) (Pubitemid 40116617)
16. Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J. Clin. Sleep Med. 4, 456-461 (2008)
17. Zee PC, Wang-Weigand S, Wright KP Jr, Peng X, Roth T. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med. 11, 525-533 (2010)
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, VA, USA (2000)
19. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J. Clin. Sleep Med. 3, 495-504 (2007) (Pubitemid 47378253)
20. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry 63, 1149-1157 (2006) (Pubitemid 44500632)
21. Lewy A, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol. Int. 23, 403-412 (2006) (Pubitemid 43739051)
22. Wilson SJ, Nutt DJ, Alford C et al. British Association for Psychopharmacology consensus statement on evidence-based treatment for insomnia, parainsomnias and circadian rhythm disorders. J. Psychopharmacol. 24(11), 1577-1600 (2010)
23. Estivill E, Bové A, Garca-Borreguero D et al. Consensus on drug treatment, definition and diagnosis for insomnia. Clin. Drug. Investig. 23(6), 351-385 (2003) (Pubitemid 36724156)
24. Efficacy and Safety of Ramelteon on Chronic Insomnia http:// clinicaltrials.gov/ct2/results?term=NCT00915135